May 10 (Reuters) - Strongbridge Biopharma plc:
* REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* Q1 NON-GAAP LOSS PER SHARE $0.33
* Q1 EARNINGS PER SHARE VIEW $-0.40 — THOMSON REUTERS I/B/E/S
* INCREASED FULL-YEAR 2018 REVENUE GUIDANCE FOR KEVEYIS TO $18 TO $20 MILLION
* STRONGBRIDGE HAD $92.4 MILLION OF CASH AND CASH EQUIVALENTS AND $86.5 MILLION IN OUTSTANDING DEBT AS OF MARCH 31, 2018
* MACRILEN (MACIMORELIN) PRODUCT LAUNCH ON TRACK FOR JULY 2018 Source text for Eikon: Further company coverage:
